Antimicrobial resistant pathogens can cause local outbreaks or be carried within and across national borders. While AMR can affect everyone, everywhere, the causes and consequences of AMR differ in developing and emerging markets compared to developed countries.
We are focused on the development of vaccines to protect people from severe bacterial infections and exploring innovative technologies to treat those infected. Through new scientific approaches, our goal is to shift the paradigm in how we address AMR.
We are excited about the progress of our ExPEC vaccine candidate in Phase 3 development which aims to prevent invasive ExPEC Disease caused by the nine most relevant serotypes of ExPEC.
Advocating to end drug-resistant TB: the #1 contributor to AMR death gobally
Accelerating early-stage science to develop and deliver new TB treatments from the lab to the lastmMile
Johnson & Johnson launches network of global health discovery centers that aim to speed up science and tackle pandemic threats
Johnson & Johnson announces five initiatives to help find the ‘Missing Millions’ of undiagnosed people living with tuberculosis
1 Antimicrobial Resistance. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Last accessed: October 2021.
2 Pelfrene, E., et al. Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?. Antimicrob Resist Infect Control 10, 21 (2021). https://doi.org/10.1186/s13756-021-00893-z. Last accessed: November 2021.
3 Review on antimicrobial resistance. Tackling drug-resistant infections globally: Final report and recommendations. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Last accessed: October 2021.
*NOTE: The statistics around infections and deaths caused by ExPEC are based on figures in the U.S. which have been multiplied by a factor of 22, extrapolating the U.S. figure to a global population figure.